BORA PHARMACEUTICALS LTD
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services fo… Read more
BORA PHARMACEUTICALS LTD (6472) - Total Assets
Latest total assets as of September 2025: NT$43.74 Billion TWD
Based on the latest financial reports, BORA PHARMACEUTICALS LTD (6472) holds total assets worth NT$43.74 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BORA PHARMACEUTICALS LTD - Total Assets Trend (2019–2024)
This chart illustrates how BORA PHARMACEUTICALS LTD’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BORA PHARMACEUTICALS LTD - Asset Composition Analysis
Current Asset Composition (September 2024)
BORA PHARMACEUTICALS LTD's total assets of NT$43.74 Billion consist of 51.7% current assets and 48.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 12.8% |
| Accounts Receivable | NT$11.44 Billion | 25.1% |
| Inventory | NT$5.50 Billion | 12.1% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$3.78 Billion | 8.3% |
| Goodwill | NT$3.66 Billion | 8.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how BORA PHARMACEUTICALS LTD's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BORA PHARMACEUTICALS LTD's current assets represent 51.7% of total assets in 2024, an increase from 36.8% in 2019.
- Cash Position: Cash and equivalents constituted 12.8% of total assets in 2024, down from 13.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 25.1% of total assets.
BORA PHARMACEUTICALS LTD Competitors by Total Assets
Key competitors of BORA PHARMACEUTICALS LTD based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
BORA PHARMACEUTICALS LTD - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - BORA PHARMACEUTICALS LTD generates 0.42x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, BORA PHARMACEUTICALS LTD generates $8.64 in net profit.
BORA PHARMACEUTICALS LTD - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.30 | 1.82 | 1.16 |
| Quick Ratio | 1.07 | 1.40 | 0.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$4.27 Billion | NT$ 10.70 Billion | NT$ 1.74 Billion |
BORA PHARMACEUTICALS LTD - Advanced Valuation Insights
This section examines the relationship between BORA PHARMACEUTICALS LTD's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.56 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 82.0% |
| Total Assets | NT$45.60 Billion |
| Market Capitalization | $1.04 Billion USD |
Valuation Analysis
Below Book Valuation: The market values BORA PHARMACEUTICALS LTD's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: BORA PHARMACEUTICALS LTD's assets grew by 82.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BORA PHARMACEUTICALS LTD (2019–2024)
The table below shows the annual total assets of BORA PHARMACEUTICALS LTD from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-09-30 | NT$45.60 Billion | +82.02% |
| 2023-09-30 | NT$25.05 Billion | +10.06% |
| 2022-09-30 | NT$22.76 Billion | +208.74% |
| 2021-09-30 | NT$7.37 Billion | +5.26% |
| 2020-09-30 | NT$7.00 Billion | +107.06% |
| 2019-09-30 | NT$3.38 Billion | -- |